Theravance Biopharma Inc (TBPH) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.02 (-0.12%), Market cap $0.84B, P/E ratio 7.27, 52-week low–high $9.15 ~ $20.74.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and
Financial statements, price targets, institutional (13F) holdings and related news for Theravance Biopharma Inc are updated in real time on BlackAll Trade.
Theravance Biopharma Inc trades at $17.02 (-0.12%). Real-time quotes and charts are available on BlackAll Trade.
Theravance Biopharma Inc has a market cap of about $0.84B. Its P/E ratio is 7.27.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for t